Groundbreaking Brain Cancer Vaccine Trials
A phase III clinical trial of the DCVax-L cancer vaccine, conducted at Brown University Health Cancer Institute and other centers internationally, has shown the vaccine extended the median survival rate of both newly diagnosed and recurrent glioblastoma. The trial results were reported in a publication in the prestigious cancer journal JAMA Oncology.